Evosep, a Copenhagen, Denmark-based bioscience company working on the standardization of proteomics for clinical use, received $40M in funding.
The round was led by Novo Holdings. Given the investment, Stephen Van Helden, Principal, Novo Holdings, who is based in San Francisco, will join Evosep’s Board of Directors.
The company intends to use the funds to advance clinical applications of proteomics enabled by its standardized liquid chromatography platform, and further expand its presence globally, especially in the US market.
Founded in 2016 by proteomics technology pioneer Ole Vorm, and led by CEO Christian Ravnsborg, Evosep aims to improve quality of life and patient care by unlocking LC-MS for drug discovery and innovating how protein-based clinical diagnostics are performed across panels with multiple protein biomarkers. Its platform offers a high-sample-throughput capability with reproducibility (i.e., valuable, useable data) between sample runs and across instruments and sites. The technology shapes the potential of proteomics by developing valuable applications, enabling widespread use, and the development of clinically meaningful protein-based diagnostics.
FinSMEs
09/01/2023